Nano Cap New Millennium Growth Fund L P Acquires New Holdings in CRISPR Therapeutics AG $CRSP

Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, HoldingsChannel reports. The fund acquired 17,500 shares of the company’s stock, valued at approximately $918,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its position in CRISPR Therapeutics by 98.3% during the third quarter. JPMorgan Chase & Co. now owns 593,416 shares of the company’s stock valued at $38,459,000 after purchasing an additional 294,222 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in CRISPR Therapeutics by 44.7% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 283,111 shares of the company’s stock valued at $18,348,000 after purchasing an additional 87,509 shares during the period. O Neil Global Advisors Inc. bought a new position in CRISPR Therapeutics during the third quarter valued at approximately $10,934,000. UBS Group AG raised its position in CRISPR Therapeutics by 7.7% in the fourth quarter. UBS Group AG now owns 2,524,144 shares of the company’s stock worth $132,366,000 after acquiring an additional 180,580 shares during the period. Finally, SR One Capital Management LP raised its position in CRISPR Therapeutics by 94.4% in the third quarter. SR One Capital Management LP now owns 2,038,763 shares of the company’s stock worth $132,132,000 after acquiring an additional 989,812 shares during the period. Institutional investors own 69.20% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on CRSP. Chardan Capital increased their price target on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a research report on Saturday, February 14th. Needham & Company LLC increased their price target on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 13th. Citizens Jmp decreased their price target on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a research report on Friday, January 30th. TD Cowen increased their price target on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a research report on Friday, February 13th. Finally, Wall Street Zen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $65.47.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 3,182 shares of the stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $148,853.96. Following the completion of the sale, the general counsel directly owned 94,308 shares of the company’s stock, valued at $4,411,728.24. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Naimish Patel sold 3,150 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $48.26, for a total transaction of $152,019.00. Following the completion of the sale, the insider directly owned 13,143 shares of the company’s stock, valued at approximately $634,281.18. This trade represents a 19.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 42,749 shares of company stock valued at $2,100,723 over the last three months. Corporate insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP opened at $49.90 on Friday. The firm has a fifty day moving average price of $50.87 and a 200-day moving average price of $53.28. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.97 and a quick ratio of 17.96. The stock has a market cap of $4.81 billion, a PE ratio of -8.02 and a beta of 1.74. CRISPR Therapeutics AG has a 1 year low of $35.38 and a 1 year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. The firm had revenue of $1.46 million during the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%. Equities analysts anticipate that CRISPR Therapeutics AG will post -5.08 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.